Skip to main content
MD Wolverine

BPC-157 TB-500 sources

The papers and agency documents behind the recovery argument, with the full citation details below.

Reading list

The 2025 orthopaedic systematic review is the starting point for the imbalance between preclinical work and human injury evidence. The broader BPC-157 narrative review covers the small human pilot record beyond that narrower injury scope.

For actin, I start among the resting human white blood cells, followed by the hybrid-protein structure. The first establishes a cellular setting; the second supplies molecular detail. The full-length thymosin beta-4 tolerability studies have their own entries, distinct from the fragment-identification work.

The FDA documents cover the withdrawn nominations, compounding framework and committee calendar. Their different purposes matter when a claim concerns permission to prepare a medicine. The bibliography also retains the tumor-model and equine detection papers discussed in the source record.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  5. Cassimeris L, Safer D, Nachmias VT, Zigmond SH. Thymosin beta 4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes. J Cell Biol. 1992;119(5):1261-1270. ↗
  6. Tokura Y, et al. Muscle injury-induced thymosin beta4 acts as a chemoattractant for myoblasts. J Biochem. 2011;149(1):43-48. ↗
  7. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. ↗
  8. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
  9. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  10. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  11. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (Entries for 'BPC-157' and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' in FDA's 'Bulk drug substances nominated but withdrawn' table, with safety rationales retained; both nominations were withdrawn by their nominators, which gives no drug approval or Category 1 placement; page content current April 22, 2026; verified 2026-09-17.) ↗
  12. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Category definitions; the 503A/503B framework; the January 7, 2025 change to categorization of newly nominated substances; verified 2026-05-29.) ↗
  13. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Public calendar listing BPC-157 and TB-500, with KPV and MOTS-c, as bulk drug substances 'being considered for inclusion on the 503A Bulks List' — an agenda for discussion, not a decision; verified 2026-05-29.) ↗
  14. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003. ↗
  15. Ho ENM, et al.. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. ↗
  16. Ruff D, et al.. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. ↗
  17. et al.. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021. ↗